Condition
Solid Cancers
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsNCT07371663 · 2025-12-03
RECRUITINGSpatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid TumorsNCT07058948 · 2025-07-01
RECRUITINGClonal Hematopoiesis Chemotherapy and Radiation Effects StudyNCT07675967 · 2025-04-04
RECRUITINGA PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR PathwayNCT06614751 · 2024-11-01
NOT_YET_RECRUITINGA Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerNCT01296555 · 2011-03-16
TERMINATEDCommon interventions
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Trial status mix
RECRUITING3
NOT_YET_RECRUITING1
TERMINATED1
Phase mix
PHASE13
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.